Physics, makers of diagnostic radiopharmaceuticals and molecular imaging agents. | GE HealthCare plans to take full control ...

With new data on petosemtamab set to be presented at the European Society for Medical Oncology Asia Congress, Merus believes ...

Novocure has cleared a phase 3 clinical study in pancreatic cancer, showing its tumor-treating electric fields could help ...

Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...

Cancer-focused Alligator Bioscience is clamping down on costs, laying off 70% of its team in efforts to save around $6 ...

The FDA has rejected Applied Therapeutics’ attempt to win approval on the strength of a failed phase 3 trial, triggering a 75 ...

Each year, we assemble our list of marquee names in the Fierce 15—featuring the most innovative private companies and ...

GE HealthCare has unveiled a new mammography system with artificial intelligence-powered features that it says are aimed at ...

Alector’s AbbVie-partnered Alzheimer's disease asset has failed to slow disease progression in a phase 2 study, the latest in ...

Roche has struck a $1.5 billion deal to buy Poseida Therapeutics. The takeover will establish off-the-shelf cell therapies, ...

Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for ...

Roche’s Skyscraper-01 has fallen down. The phase 3 trial found adding the TIGIT candidate tiragolumab to a checkpoint ...